Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tolerated dose (MTD), immune responses, time to progress...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Lum, Lawrence G., Thakur, Archana, Choi, Minsig, Deol, Abhinav, Kondadasula, Vidya, Schalk, Dana, Fields, Kristie, Dufrense, Melissa, Philip, Philip, Dyson, Gregory, Aon, Hussein D., Shields, Anthony F.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7480816/
https://ncbi.nlm.nih.gov/pubmed/32939319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1773201
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars